Pfizer (NYSE:PFE) Shares Up 1.8% – Time to Buy?

Pfizer Inc. (NYSE:PFE)’s stock price was up 1.8% during trading on Friday. The stock traded as high as $30.67 and last traded at $30.48. 37,080,873 shares were traded during mid-day trading, a decline of 6% from the average session volume of 39,629,590 shares. The stock had previously closed at $29.95.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Five investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.65.

Pfizer Trading Up 1.8%

The company’s 50-day moving average is $28.55 and its 200-day moving average is $26.79. The firm has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a P/E/G ratio of 2.07 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pathway Financial Advisers LLC increased its position in shares of Pfizer by 17.3% during the third quarter. Pathway Financial Advisers LLC now owns 67,908 shares of the biopharmaceutical company’s stock worth $1,937,000 after acquiring an additional 10,005 shares in the last quarter. Chicago Partners Investment Group LLC lifted its position in Pfizer by 79.4% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 173,666 shares of the biopharmaceutical company’s stock valued at $5,215,000 after acquiring an additional 76,849 shares in the last quarter. Optimist Retirement Group LLC lifted its position in Pfizer by 2.7% in the 3rd quarter. Optimist Retirement Group LLC now owns 96,047 shares of the biopharmaceutical company’s stock valued at $2,739,000 after acquiring an additional 2,518 shares in the last quarter. Signet Investment Advisory Group Inc. boosted its stake in Pfizer by 6.0% in the 3rd quarter. Signet Investment Advisory Group Inc. now owns 169,268 shares of the biopharmaceutical company’s stock worth $4,828,000 after purchasing an additional 9,550 shares during the period. Finally, MH & Associates Securities Management Corp ADV boosted its stake in Pfizer by 0.3% in the 3rd quarter. MH & Associates Securities Management Corp ADV now owns 157,296 shares of the biopharmaceutical company’s stock worth $4,486,000 after purchasing an additional 529 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.